




Supplementary Figure 1.











Supplemental Table 1. PON1-Arylesterase in Controls and T2DM subjects with similar age and gender prevalence

	T2DM*	Control*	p value
	(n=85)	(n= 85)	
Arylesterase (KU/L)	73 ± 24	82 ± 20	0.003
Age (years)	63 ± 8	65 ± 9	0.700
Gender (women/men)	35/50	35/50	1.00
BMI (Kg/m ²)	31 ± 4	27 ± 5	< 0.001
Smoking (% never/ex/current)	39 /43/18	35/37/18	< 0.001
Glucose (mg/dL)	145 ± 35	99 ± 9	< 0.001
Hypertension (%)	80	36	< 0.001

Data are expressed as means \pm standard deviations for continuous variables and number or percentage within the group for categorical variables. Abbreviations: BMI, body mass index

^{*}Subsets extracted from total sample

Supplemental Table 2. Main characteristics and serum levels of PON1-Arylesterase, PON1-Lactonase and Lp-PLA2 activities of Controls and T2DM subjects (Lipoprint subsample, n=292)

	T2DM	Controls	p value
	(n=90)	(n= 202)	
Age (years)	66 ± 10	56 ± 11	< 0.001
Gender (Women/Men)	35/55	139/63	< 0.001
BMI (Kg/m²)	32 ± 5	26 ± 5	< 0.001
Glucose (mg/dL)	149 ± 40	98 ± 12	< 0.001
Smoking (% never/ex/current)	34 /46	49/1/49	< 0.001
Hypertension (%)	93	58	< 0.001
Dyslipidemia (%)	98	54	< 0.001
Enzyme activities			
Arylesterase (KU/L)	75 ± 20	96 ± 31	< 0.001
Lactonase (U/L)#	94 ± 25	98 ± 22	0.274
Lp-PLA2 (U/L)#	15 ± 5	14 ± 3	0.431

Data are expressed as means \pm standard deviations for continuous variables and number or percentage within the group for categorical variables

Abbreviations: BMI, body mass index

^{*}Lactonase was measured in 152/202 Controls; Lp-PLA₂ was measured in 111/202 Controls